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ABSTRACT 
 
The lower respiratory regions of the lung boast over 900 million alveoli with a 
combined 85 m2 of surface area of near direct access to the bloodstream. Within the last 
century the immense potential of the deep lung as asite for the delivery of drugs has 
begun to be exploited and today pulmonary delivery of aerosolized therapeutic is 
commonplace. High inter- and intra-patient variability in dosing continues to plague the 
industry. Currently, only a few researchers are actively seeking to mitigate the sources of 
physiological variability. This study seeks to prove that careful selection of a particle size 
distribution can improve inhaler performance and reliability over a range age and 
inhalation velocity. In this study, lung morphometry and flow rate were considered to be 
the uncontrollable sources of inter- and intra-patient variability. Three populations 
representing different lung geometries were explored: adults aged 14 to 21 years old, 
children aged 1 to 9 years old and adults with severe lung remodeling. The range of flow 
rates considered was customized to the population based upon normal to severe asthmatic 
breath rates specific to that age group. Classical equations predicting deposition were 
utilized in conjunction with cadaver data to establish particle deposition behavior as a 
function of age and velocity.  The coefficient of variation within an age group and over 
the range of velocities was minimized to obtain an optimized particle size distribution. 
This investigation demonstrated that current devices favor the healthy adult leaving 
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critical populations such as infants and children with extremely poor deposition 
efficiency. The optimal particle size distributions for the adult, adult with airway 
remodeling and child cohorts were monodispersed with mean diameters of 3.6, 2.8 and 
1.2 µm respectively. These results demonstrate that one particle size distribution cannot 
be used to treat the entire population of inhaler users and greater attention should be paid 
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Cc – Cunningham slip correction factor 
D – Airway diameter 
d – Particle diameter 
Dd – Diffusion coefficient 
FRC – Functional residual capacity 
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k – Boltzmann’s constant(1.38x10-23 
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RH – Relative humidity 
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xd – Root mean square displacement 
xs – Settling distance 
α – Bifurcation angle 
θ – Posture angle 
λ – Mean free path of air  
ρf – Fluid density 
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CHAPTER ONE: INTRODUCTION 
Background 
Administering therapeutics via the respiratory tract has many distinct advantages 
over other delivery routes. First, when used for the reatment of diseases of the lung, 
direct application yields rapid response, reduces th  dose required and lessens the risk of 
negative side effects.  Also, the branching nature of the lung, with 24 generations, 900 
million alveoli, and a surface area upwards of 85 m2 with only 0.2-0.6 µm between the 
airway the blood stream, all of which make the respiratory zone ideal for drug absorption 
into the blood stream [1]. Direct access to the blood stream via respiration into the lungs 
allows drugs to bypass the gastrointestinal tract – a huge advantage over orally 
administered medicine in that the potential loss or degradation of a therapeutic due the 
digestive system enzymes is avoided. While the blood stream can also be directly 
accessed by delivering drugs intravenously, this route can be painful and patient 
compliance is often low as a result. As there is no pain associated with the inhalation of 
aerosolized therapeutics, patient compliance is much better than with intravenous 
delivery. Furthermore, the delivery would not need to be done by a trained medical 
professional as is usually the case for intravenous delivery. Even though there is this 
immense potential for pulmonary delivery, the major d wnfall in delivery devices today 
is efficiency.  
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Drug deposition efficiency to patients’ lungs has increased recently from <20% to 
>50% of the delivered dose as device technology has m tured to control particle size, 
distribution and injection velocity. Driving this improvement is the fact that, despite the 
presence of at least sixty-five aerosol devices already on the market [2], there is still a 
significant and growing need for more patient-operation-independent devices that provide 
the reliable and repeatable drug release that pulmonary delivery affords [3]. If this 
limitation can be overcome, the potential of the lungs as a drug administration route 
could be boundless.  
It is important to understand how drugs are delivered to lung before one can seek 
to improve delivery efficiency. Currently, drugs are delivered to the respiratory tract by 
aerosolizing the therapeutic agents as dry bulk powders, emulsions, solutions, or solid-
particle suspensions [1]. These formulations can the  be inhaled by the patient. The drug 
then either treats the lung topically or is absorbed into the blood stream. The 
aerosolization devices most commonly used are: (1) dry-power inhalers (DPI), (2) 
nebulizers and (3) propellant driven metered dose inhalers (pMDI).  
Dry-power inhalers generally utilize the inspiratory flow of the patient to 
discharge and mix the dry powder into the air stream for drug delivery (Figure 1.1). 
However, DPI flow-rate-independent devices that usepr ssurized air to disperse the 
drugs also exist. [1] It is important to note here that although dispersion in the latter DPI 
device is flow-rate-independent, the deposition within the lung itself is still highly flow-
rate-dependent, so the breath rate of the user still affects deposition.  
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Jet nebulizers produce liquid droplet aerosols using high velocity air to shear 
droplets from a bulk liquid which produces small particles between 1 and 5 µm in 
diameter (Figure 1.1). The generated aerosol is then allowed to circulate within a 
reservoir prior to inhalation by the patient.  Other devices exist that produce liquid 
aerosol droplets between 50 and 200 µm by forcing the liquid through a small orifice, but 
this range of diameters is too large to make it into the lung therefore those devices are 
used exclusively for oral and nasal deposition [1].  
A pMDI inhaler creates aerosols from liquid emulsions, solutes or micronized 
power within a propellant by releasing a known volume of pressured therapeutic particle 







Figure 1.1: Schematics of Commercialized Device Operation. 
Top left: Metered dose inhaler (http://www.asthma.ca/adults/treatment/meteredDoseInhaler.php)  
Top right: Dry-power inhaler (http://www.asthmameds.ca/diskus.php)  
Bottom center: Jet nebulizer (http://www.medscape.com/viewarticle/579507_4) 
 
 Where therapeutic particles deposit on many variables including tongue position, 
injection velocity, injection angle, airway elasticity, particle properties, physiological 
dimensions and flow rate.  
The position of the tongue contributes significantly o the variation in the 
geometry of the upper airway, and most importantly the cross-sectional area of the oral 
cavity [4]. As the airway geometry in the oral cavity is influenced by the position of the 
tongue, the number of particles that deposit will be affected. Consequently, the deposition 
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in the lower regions of the lung will also be affected. Tongue position can also affect the 
flow in the oral cavity with respect to the injection angle of the aerosol, as shown by the 
studies conducted by Fadl et al [5]. They revealed that when the aerosol jet is angled 
towards the tongue, boundary layers develop and the flow behaves similar to that of flow 
over a plate. This asymmetric flow profile gives rie to larger deposition at the back of 
the throat because the jet velocity farther away from the tongue is not slowed and the 
particles cannot follow the streamlines down into the lower airways. Fadl et al argue that 
an optimum angle can be found which will foster a more “symmetrical” velocity profile 
causing the jet to slow down both at the interface with the tongue and with the roof of the 
mouth therefore maximizing penetration into the lower airways [5].  
 The inspiratory and injection flow rates are also key factors of deposition in many 
stages of the therapeutic delivery process. For delivery devices such as the DPI which 
rely on the user’s inspiration flow rate to disperse the therapeutic, inspiration with too 
low of a breath rate could result in little to no therapeutic being dispensed from the 
inhaler. In fact, insufficient flow rates for dispersion of the dose are quite common 
especially in users over 60 years old [6].A study showed that, depending on which DPI 
inhaler is being used, as much as 38.9% of users between 18 and 59 years old and 66% of 
users over 60 were unable to produce sufficient airflow to properly dispense the dose [6]. 
At the opposite end of the spectrum, pMDIs deliver a dose within a very short time, 
approximately 0.1 second, which means that the particles are injected at very high 
velocities.   At high velocities particles have more inertia and have a tendency impact at 
the back of the throat where there is a change in flow direction down into the trachea  [1].  
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Once the aerosol spray makes it past the upper airways and into the trachea, the 
mechanism by which a particle deposits in the lung depends largely on the properties of 
the particle, the geometry of the lung and the prope ties of the fluid carrying the particle. 
If a particle is of a size and density such that it has enough inertial energy to leave the 
stream lines when there is a change in direction of the flow and its stopping distance is 
greater than or equal to its distance from the wall, it will collide with the wall of the lung 
and thus deposit via inertial impact. When a particle’s diameter is less than or equal to the 
mean free path of the fluid, random motion results from repeated particle collision with 
the neighboring fluid molecules. Given sufficient time this random motion could 
eventually cause a particle to collide with the lung wall and deposit. If this diffusive time 
is less than the residence time of the particle within he tube then it is said to have been 
deposited by Brownian motion. Finally, gravitational forces will act on the particle. 
Gravitational settling times will be a function of tube angle in relation to gravity and tube 
diameter. If the settling time is less than the resid nce time for the particle then 
deposition by sedimentation occurs. Charged particles an also experience electrostatic 
forces but because of the humid environment of the lung, inhaled particles are assumed to 
be charge neutral. A visual representation of the mechanisms of deposition considered in 




Figure 1.2: Mechanisms of Deposition in the Lung. [This image was modified from and image found at 
http://www.coheadquarters.com/PennLibr/MyPhysiology/lect6p/lect6.02.htm]  
  
Since the efficiency and efficacy of pulmonary therapeutic delivery is affected by so 
many different variables, control and mitigation techniques are constantly being 
researched, engineered and commercialized. The position of the tongue and the angle at 
which the aerosol jet is administered can be controlled simply by using a suitable 
mouthpiece attached to the delivery device.   
 Flow rates, on the other hand, are significantly more complex. Currently, injection 
velocity is commonly reduced in pMDI inhalers using a device called a ‘spacer’ which 
can come in many shapes and sizes from a simple tube to a 750 mL holding chamber one 
of which is pictured below in Figure 1.3. As the aerosol jet enters the spacer, the jet is 
slowed down by the resistance in the air and the particles are allowed time to evaporate. 
This combination results in a slower moving spray made up of smaller particles which 
increases the likelihood that they will make it into the trachea without impacting at the 
back of the throat and reduces the need for coordinatio  between actuation and inhalation 
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[7]. A device called a “Soft Mist” inhaler has recently been developed to also mitigate the 
flow rate and coordination issue addressed by the spacers as discussed previously. The 
“soft mist” inhaler, pictured below in FIGURE 1.3, forces a metered dose of therapeutic 
through a specifically engineered nozzle to produce an aerosol that has a lower injection 
velocity and a much longer cloud generation time, 1.5 s, than the pMDI counterpart 
without the bulky spacer [8]. For the inspiratory flow rate requirements of a DPI inhaler, 
a device called the “Novolizer” was developed which gives the user feedback as they use 
the device (Figure 1.3). A Novolizer has a display window with an indicator that remains 
green until the user generates sufficient inspiratory fl w; it then turns red indicating that 
the drug has been delivered. This device also has a trigger flow valve that only releases 
the dose when the proper flow rate is achieved, so the user can be sure that a proper dose 
was administered [9]. 
  
 
Figure 1.3: Commercialized Injection Velocity Control D
Top left: Spacer (http://www.asthma.ca/adults/treatment/spacers.php
(http://www.respimat.com/functions_and_use/howitworks.html
(http://www.novolizer.com/wms/novolizer/inhaler/correctinhalation
 The remaining variables, then, are those which affect d position once the spray makes 
it into the trachea namely: particle proper
Predicting deposition in the deep lung becomes complex at this point because neither a 
person’s airway geometry nor the rate at which they breathe can be considered 
controllable variables. The unpredictable natur
impossible for physicians to know how much therapeutic their patients are actually 
receiving. This means that over




)  Top right:  Soft Mist inhaler 
). Bottom:  Novolizer
).
 
ti s, flow properties, and airway geometry. 
e of lower airways makes it nearly 







 The objective of this study is to use the characteistics of an aerosol spray to reduce the 
variability in deposition caused by the patient-to-patient fluctuations in airway geometry 
and inspiratory breath rate.  The International Pharmaceutical Aerosol Consortium on 
Regulation and Science (IPAC-RS) has suggested that particle size distributions be a 
focus of study for inhaled pharmaceutical bioavailability [3]. Also, no standards have 
been set with for a minimum of delivered particles [3], so we hypothesize that a 
distribution of particles exists which will minimize the variability in deposition in order 
to provide more reliable patient dosing. Even if the reduced variability comes at the 
expense of the total volume deposited, we hope that reliable deposition will aid in the 
proper dosing of patients. 
 Other research exploring particle size distribution n relation to deposition does not 
seek out an optimum distribution, but instead just reports the effects different particle 
sizes have on deposition or lung response.  For instance, a study done by Johnson et al. 
revealed that bronchodilation response to salbutamol was significantly better when 3.3 
µm diameter particles were used as opposed to a larger 7.7 µm particle. This suggests the 
particle diameter should be selected to target specific areas of the lung where the drug 
can be most effective [2]. Another study done by Rees et al. [10]explored the clinical 
effect of three different particle size ranges (<5 µm, 5-10 µm and 10-15 µm) on 
asthmatics and found that the smallest particles performed the best because they penetrate 
the restricting airways better than larger particles. [2].  Zanen et al. [11] investigated 
three particle sizes in the range ≤5 µm (1.5 µm , 2.8 µm and 5 µm)  and found that if the 
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particles are too big they do not penetrate deep enough into the lung, but if they are too 
small they can deposit too deeply into the fringes of the lung and therefore have no 
therapeutic effect [2]. This suggests that particle size should be chosen with respect to a 
patient’s disease state. In their study, Zanen et al.[12] found that a particle size of 2.8 µm 
is most effective for patients with mild to moderat sthma, but for severe asthma treated 
with β2 agonist or anticholinergic a diameter closer to 3 µm would be best [2]. Each of 
these studies shows that particle size is critical when treating diseases of the lung, but 
they only talk about optimum diameters with respect to argeting specific diseases on 
specific types of patients. A more encompassing approach to particle size optimization 
needs to be taken to economically address the needs of the population.  
 The current work will explore deposition reliability in the deep lung using both 
empirical and derived probabilistic equations for deposition in a formal optimization 
scripted in MatLab. We will not address sources of variability that can be managed using 
commercial techniques like injection velocity and angle. Instead, the focus will be on 
engineering a polydisperse spray that minimizes variability from the uncontrollable, 
physiological sources: lung morphometry and flow rate. A baseline of current PDI and 
pMDI reliability performance was set and four particle size distributions were tested in 
the optimization routine to gauge relative performance for a 21-year-old male over a 
range of flow rates from 10 (healthy) to 30 (severe asthmatic) L/min. The effect of 
different deposition equations on the optimization s also explored. From here, two 
distributions were chosen and the optimization was run with the addition of the varied 
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lung geometries of an 18-, 14.08- and 14-year-old an gain for four children’s lung 







CHAPTER TWO: METHODS 
 
To optimize a polydisperse spray size distribution entering the upper airways of a 
human lung that results in the least variability of deposited drug dose to the lower 
lung regardless of human physiology or health state requires calculation of particle 
deposition by impaction, sedimentation and diffusion in every generation or branch of 
a human lung. These deposition mechanisms are depennt on airway lengths and 
diameters, which are functions of size, weight or age s well as lung volumetric flow 
rates linked to health state and particle characteristics.   
Assumptions 
For deposition correlations used in this study to be valid, certain assumptions 
about the particles, the lung morphometry and the flow must be made.  First, oral 
cavity (i.e., tongue position), injection angle, and breath velocity aligning to injection 
velocity is assumed to be controllable by the devic. This means that deposition 
occuring in the extrathoracic region is not taken into consideration and deposition is 
only evaluated from the trachea to the deep lung. Second, the applicable particle size 
range (diameter = 1 to 7 m) was drawn from literature and it is consistent with what 
others have found to consistently make it through the oral cavity and larynx. This also 
means that the section of the respiratory system that includes the larynx is not 
modeled. This assumption is not ideal as the larynx controls what enters the trachea, 
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but accurate modeling of the flapping behavior of this portion of the respiratory tract, 
requires a fluid-solid interaction model which is outside the scope of the current 
study.  
The particles are assumed to be water with a density, ρp, of 1000 kg/m
3 and a 
viscosity, µp, of 8.90E−4 kg/m-s. A constant dose of 1.2 µL of particles is 
homogenously distributed throughout the inhaled volume. This dose was chosen 
based upon guidelines put forth by the FDA which state that in a 25 to 100 µL 
volume, only a few micrograms to a few milligrams of active ingredients should be 
present. Using water for the particle properties is also acceptable. Not only are most 
pharmaceutical densities near that of water, but the diameter of the particle in this 
study would then be the aerodynamic diameter for particles of different densities.  
Pharmaceutical companies often describe their particles n terms of their aerodynamic 
diameter, which is the diameter of a water droplet tha has the same settling velocity 
as the particle in question. In other words, a water droplet of size dae behaves the 
same, aerodynamically, as a corresponding particle of diameter, d.  
The fluid being used is 99.5% RH air [13] with a density, ρf, of 1.112 kg/m
3 and a 
viscosity, µf , of 1.843E-5 kg/m·s which is representative of the conditions found in 
the lung.  The equations used assume that the particles are spherical and have a 
density much larger than the fluid. This is a valid assumption given the 1000 kg/m3 
particle density, ρp, and the 1.112 kg/m
3 fluid density.  Other properties used include 
the mean free path, λ of 0.072 µm at 37ºC and 1 atm, the Boltzmann’s constant, k, of 
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(1.38x10-23 J•K-1), and the temperature, T, of 37 ºC. The flow is considered to be 
incompressible and hygroscopic affects to the particles are ignored.  
Deposition Calculations 
 To approximate deposition, expressions predicting he probability that a 
particle will deposit via each of the mechanisms dicussed in Chapter 1 need to be 
utilized. Throughout the last century, scientists and mathematicians have solved 
fundamental fluid mechanics equations and fit experim ntal data to derive these 
expressions for deposition by diffusion (Brownian motion), sedimentation and 
impaction. 
Diffusion/Brownian Motion 
 Since diffusion is motion due to multiple collisions with the molecules of 
the fluid, the exact movement of the particle is not easily calculated mathematically. 
The general motion of the particles can be approximated by solving the convection-
diffusion equation. This equation was solved for an aerosol concentration assuming 
plug flow by Buchwald (1921), and Fuchs (1964), to come up with the following 
equation for deposition resulting from Brownian diffusion [13]: 




This equation requires an approximation of λm which is provided by Abramowitz 
and Stegun (1981) [13]: 
16 
 
	     18  1248  120928158  4017431681058$  % & 1'( ,    *+, 
 &-  14( . 
 Because the previous equations would need to be evaluated using 
thousands of terms to be fully accurate, an empirical approximation was needed. This 
approximation states that for values of ∆ greater than 0.16853 the probability of 
deposition by diffusion can be taken to be one, but if  ∆ is less than or equal to 
0.16853, the following equation  can be used to calcul te Pd  [13]: 
  0.1643850. 
$ 1 exp 3.94325  0.219155560
  0.0346876560





 The equation above calculates deposition within 2% of the actual solution 
discussed earlier for 10-9 < ∆ <0.3. This range is acceptable given the ∆’s calculated 
in this study. This being said, Brownian motion is sometimes insignificant in 
comparison to sedimentation. To characterize particle movement due to random 
collisions with molecules, the root mean square displacement, xd, must be calculated 
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which is a function of the diffusion coefficient, Dd, and the time spent in a given 
generation, t (Finlay,2001).   
D  E2FG  
where,  
F  :;<=3.?@ 
A ratio of the displacement, xd, to the settling distance, xs, defined below, can then 
indicate whether or not diffusion can be ignored. If the ratio is less than 0.1 the deposition 
by diffusion is negligible.  
DH  νHJKKLMNOG 
Sedimentation 
 Sedimentation, as discussed in Chapter 1, is deposition resulting from gravitational 
forces acting on a particle. For this reason, deposition by sedimentation can be calculated 
exactly using gravitational and fluid equations. Heyd r (1975) derived an expression for 
deposition of particles by sedimentation for plug flow in a circular tube taking into 
account the posture angle, θ. In this case the posture angle was taken to be 38.24 ° which 
is an accepted value in lung modeling [13].  











Due to the complexity of the lung geometry and flow in the lung, many empirical 
correlations must be made to model deposition in the lung by impaction. Because 
these equations were derived from observations, it was necessary to compare 
calculated deposition to experimental results. The branching characteristics of the 
lung made it necessary to find experimental deposition data that incorporated 
bifurcation. The data used for comparison were those from cast data taken by Chan 
and Lippman.(1980).The deposition efficiency was plotted against the Stokes number 
of the parent generation and therefore the results could easily be compared to the 
deposition efficiency and Stokes numbers calculated using the various impaction 
equations. The Stokes number is the ratio of the inertial forces of the particle to the 
drag forces acting on the particle and as such chara terizes the movement of the 





Figure 2.1: Deposition Efficiency Calculated by Impaction Deposition Models 
and Measured Experimentally as a function of the Stokes Number. 
 
 The Stokes numbers in this study are between zero and 0.3. Since the range is so 
large and none of the correlations match perfectly, both the Uniform Cai and Yu 
correlation and the Chan and Lippmann correlation were then evaluated and 
compared. Those two were chosen because they represent an under and over 
estimation of deposition respectively. The Cai and Yu uniform flow was chosen to 
remain consistent with the diffusion and sedimentation equations. The Chan and 










<=  1  2.25 @ 
The Cai and Yu equation assuming uniform flow depends on the stokes number 
as well, but it must also take into account the diameter ratio of the daughter to parent 
generation, R/Ro, and the bifurcation angle, α.
M,`c  4 sine. f CCgh 1 bG: 
For the purposes of this lung model, the bifurcation angle, α, was taken to be 






Finally, these expressions for the fraction of particles depositing by each 
mechanism need to be combined to model the total deposition. If all modes of 
deposition are considered the following equation determines the total probability of 
deposition.  
  M]  H]  ] ]⁄  
The value of p in the exponents was taken to be 2 as recommended by the 
International Commission on Radiological Protection (ICRP). If diffusion can be 
ignored because it significance as a deposition mechanism is dwarfed by that of 
sedimentation, this simpler expression can be used: 
  M  H  MH 
Fixing the Volume of Particles   
Since this study seeks to explore the effect of a polydispersed spray on the volume 
of particles deposited in the deep lung, it is necessary to have the total dose remain 
constant while only changing the concentration of particles of a certain diameter. To 
maintain a constant dose, the following relation was used to determine the total 
number of particles within a polydispersed spray: 
jk  lm∑ f43h .,MM,Mo	JKJpNM  
Where NT is the total number of particles of a particular diameter, Vp is the total 
fixed volume, ri is the radius of the particle and Pi,diameter is the fraction of particles 
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that will be of diameter, di, based on a chosen distribution, which will be discussed 
later.   
Adjusting the Inhaled Volume 
In this model, particles are homogeneously distribued throughout the volume. 
Because the entire volume won’t make it to the deepest arts of the lung, particles 
need to be tracked in relation to their position in the inhaled tidal volume. To do this, 
a calculation is performed at each generation which determines the remaining volume 
available for deposition. The equation used for this calculation is: 
qrs  1  ∑ lMlkgKoL  
where FVi is the fraction of the adjusted cumulative volume still available, VTotal is 
the total adjusted cumulative volume, and ∑V i-1 is the sum of the adjusted volumes 
above that generation.   This volume fraction was then combined with the total 
probability of deposition, P, and the total number of particles, NT, using the equation 
below to determine the total number of particles deposited of the diameter in 
question.  
jJ]  qrsjk 
Lung Morphometry Data 
Lung Morphometry data from Ménache, et al. (2008) was used because it has data 
for various ages, both male and female, and all of the data was taken using the same 
technique. This data can be found in Appendix A. Demographic information 
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concerning the population represented in cast data is summarized in Table 2.1 and 
physiological data of the same healthy population is summarized in Table 2.2. Initial 
studies were performed on a 21-year-old male morphometry with volumetric flow 
rates varying between 10 and 30 L/min. Adult population studies included all 
individuals between 14 and 21 over the same breath range and children population 
studies included all individuals between 1 and 9 years old. 
 
Table2.1: Demographic Information of the Sample Population [14] 
 
Table 2.2: Healthy Physiological Data of the Sample Population [14] 
 
Age (yr) Gender Weight (kg) Height (cm) BMI
0.25 F 5.9 66.0 13.5
1.75 M 9.0 71.1 17.8
1.92 M 9.1 94.0 10.3
2.33 F 12.2 94.5 13.7
3.00 F 13.6 109.0 11.4
8.67 M 26.0 118.0 18.7
9.42 M 40.9 143.0 20.0
14.00 F 51.0 175.2 16.6
14.08 F 56.0 147.0 25.9
18.00 M 52.0 135.0 28.5
21.00 M 67.0 177.8 21.2
 
This data, however, was taken at total lung capacity (TLC) which is the absolute 
maximum volume the lung can hold. During a normal breath, after exhalation the 
lung is still inflated to a volume that is called the functional residual capacity (FRC). 
Even if you force all of the air out of your lung, there is still a residual volume which 
remains, as can be seen below in Figure 2.2. The volume inhaled during a normal 
breath cycle is called the tidal volume 
normal breath, the data was scaled to be FRC + TV/2, or the volume of half of a full 
breath. By taking the volume in the middle of the cycle, the average volume is being 
used and the airway diameters from 
accordingly. 




[15]. Since TLC is not the volume during a 
Ménache et al. (2008) can be adjusted 






The modeled breath cycle is important when making statements about deposition 
in the lung. The breathing cycle consists of a serie  of peaks and plateaus where the 
positive and negative slopes represent the inhale and exhale respectively. This model 
assumes that all deposition occurs during inhalation and the flow rate is constant. It is 
accurate to assume a constant flow rate because, as can be seen above in Figure 2.2, 
the slope of the inhalation portion curve is constat, except for very small sections at 
the beginning and end of inhalation, therefore flow rate is considered constant. 
Deposition Calculation  Code 
Because variability in dosing can come from multiple sources, two codes were 
developed in a computational software called MatLab which use the equations 
discussed previously to calculate the volume of particles deposited from a 
polydispersed spray in the last six generations of the lung.  
Deposition over a Range of Flow Rates 
The first code is used to optimize deposition for one lung morphometry over a 
range of flow rates which will aid in the evaluation f the design space, the impaction 
correlations, and the different distributions to be discussed later. It utilizes two nested 
‘for’ loops to calculate the volume deposited for nt just one volume flow rate, but for 
an entire range . The inner loop calculates the number of particles deposited for a 
particular diameter and stores the deposition information in a table. A study 
performed by X.G. Cui showed that particles with diameters between 1.0 and 5.0 µm 
contribute the least to deposition in the upper airw ys. Because of these results, his 
study was used to evaluate the deposition of particles with a geometric particle 
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diameter, d, from 1.0 µm to 7.0 µm in 0.2 µm increments. The increment was chosen 
to be 0.2 µm so that data would have a refined resolution while remaining within a 
realistic realm of control for particle generation. Lung morphometry data for the age 
in question is read into this loop from a file, so the code can be easily altered to 
calculate deposition for different lung models.  
The outer loop changes the velocity of the flow and deposition for all of the 
particle diameters is calculated again. An average, h althy adult breathes 
approximately 13 L/min and a person with unhealthy ungs can get upwards of 25 
L/min. For this reason, the range was chosen to be from 10 L/min to 30 L/min to 
encompass the volumetric flow rate variability of the population. A study conducted 
by Maarsingh et al. that monitored 0- to 3-year-old patients with asthma considered 
breath rate to be normal at less than 40 breaths/min and severe asthma symptoms to 
be present at greater than 60 breaths/min (Maarsingh,2005). Based on this 
information, the infant study was performed for a flow rate range from 5 to 12 L/min 
which would cover the normal, to severe asthmatic range. A range from 10 to 20 
L/min was used for the 8- and 9-year-old because it is between the normal to severe 
asthmatic range found for infants and adults. 
The deposition data is stored in a table at the end of each iteration of the inner-
loop and at the completion of the outer-loop’s cycle, the volumes deposited of each 
particle size are summed and the total deposition at each flow rate is determined. A 




Figure 2.3: Flow Rate Variability Code Flow chart. This figure summarizes code written 
to explore variability with respect to breath rates for the 21-year-old male using different 




Deposition over Different Lung Morphometries and Flow rates 
The second code was written to explore the variability in deposition when both 
flow rate and age/weight were taken into consideration. This will provide insight into 
the variability across populations and will reveal whether or not deposition variability 
can be improved using a particle size distribution optimization. In this code the 
original code (Figure 2.3) is repeated four times to calculate deposition over the range 
of flow rates for multiple age/weight lung morphometries (Figure 2.4). The flow chart 
below (Figure 2.4) represents the optimization for the adult cohort which evaluates 
the morphometry of a 21-year-old, 18-year-old, 14.08-year-old and 14-year old. This 
code was also run for a child cohort containing the lung morphometries of people 
between 1 and 9 years old and an adult cohort where t  morphometries are adjusted 
to approximate lung remodeling. Lung remodeling occurs in people who have had 
severe asthma for many years that hasn’t been properly controlled. The remodeling 
results in decreased airway diameters and also changes i  lung elasticity. A paper by 
Niimi et al. states that a 17% reduction in lung cross-sectional area is found in 
patients with severe lung remodeling. In this study, only this change in the airway is 
considered so the diameter of each airway was reduced by 42 percent to account for 




Figure 2.4: Flow Rate and Lung Morphometry Code Flow Chart. This figure 
summarizes the code written to explore variability with respect to body mass/age and 
flow rate. The area highlighted in blue from Figure 2.3 is the flow rate loop referred 
to in this figure. 
 
Determining the Number of Particles of a Certain Size within a Distribution 
Utilizing the codes described previously, the volume of particles deposited from a 
polydispersed spray of a chosen distribution can be determined using the ‘pdf’ 
function in MatLab. This function’s output is the fraction of the total number of 
particles that will be a certain diameter and its inputs are the distribution type, 
distribution defining parameters, and the diameter of interest. It has the form 
pdf(name, x, a, b) where ‘x’ is the particle diameter, ‘name’ is the distribution type 
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and ‘a’ and ‘b’ are the defining parameters. For example, to determine the number of 
particles that are 5 µm in diameter of a normal distribution with a mean of 3 µm and a 
standard deviation of 1 µm, the function would be y=pdf(‘norm’,5,3,1) and the result 
would be 0.242 meaning that out of 100 particles, 24.2 would have a diameter of 4 
µm. When employed in a loop, and using the equation for NT, the number of particles 
of each size in a controlled volume can be determined and used to compute 
deposition. It can be seen below that the number of particles of each size, plotted as a 
histogram (Figure 2.5, top), matches the plot of the distribution used (Figure 2.5, 
bottom). So the ‘pdf’ function does, in fact, introduce the correct distribution to the 






Figure 2.5: Size Distribution Input and Output Data. The top figure is a histogram 
of the number of particles calculated for the distribution within the code. The bottom 
figure is the distribution plotted using the input mean, span and a lognormal pdf 
function in MatLab.  
 
Evaluated Distribution Types 
Normal 
Four distributions were selected to explore their effect on the reliability of dosing; 
normal, lognormal, Weibull and bimodal. Normal distributions are defined by the 
mean and standard deviation of the population and are symmetric about the mean, see 















































Lognormal Distribution (mean=2.3E, std dev=0.22) 
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of applications and with a small enough standard deviation, it could also approximate 
a monodisperse droplet stream.  
 
Figure 2.6: Normal Distribution Behavior. This figure shows how the normal 
distribution changes with its defining parameters, mean and standard deviation. 
Lognormal 
The lognormal distribution is characteristic of spray droplet size distributions and 
is also defined by a mean and standard deviation and is skewed to favor smaller 
particle sizes. Figure 2.7 illustrates how the lognormal mean and standard deviation 
affect the shape of the distribution. The mean, µ, and standard deviation, σ shown in 
Figure 2.7 are the lognormal mean and standard deviation which are not to be 
confused with the normal mean and standard deviation. An equation relating the 
normal and lognormal parameter can be found below in here µ and σ are the normal 
parameters and λ and ζ are their lognormal counterparts.  
  lnμ  12 u
 
u





Figure 2.7: Lognormal Distribution Behavior. This fgure shows how the lognormal 
distribution changes with its defining parameters, the lognormal mean and the lognormal 
span (standard deviation).  
 
Weibull 
A Weibull distribution can look like a normal or a lognormal distribution depending 
on the values given to its defining parameters, the s ape factor, k, and the scale 
factor, λ. The scale factor can be likened to the mean and the shape factor controls the 
skewed nature of the distribution. It can be seen in Figure 2.8 that at a larger k the 
distribution begins to look like a normal distribution and at smaller k values it appears 
to be more lognormal. This distribution, therefore, covers the middle ground between 




Figure 2.8: Weibull Distribution Behavior. This figure shows how the Weibull 
distribution changes with its defining parameters, scale factor and shape factor. 
Bimodal 
 Finally, a bimodal distribution was considered. The bimodal distribution, 
in this case, consists of two independent lognormal distributions defined by two 
separate sets of means and standard deviations see Figur  2.9. This distribution was 
chosen because the flexibility provided by the independent lognormal distributions 
could make up for some of the variability in the deposition models. 
 
Figure 2.9 Bimodal Distribution. This figure shows how a bimodal distribution is 





As previously noted, deposition in the deep lung is dependent upon and critically 
effected by numerous parameters, so when working in a complex design space such 
as the lung it is often helpful to utilize optimization techniques to find the best 
solution. Optimization methods take a function and either minimize or maximize it 
using one or more variables. The variables being optimized start at an initial guess 
and are changed by the applied algorithm within bounds set by the user. During the 
initial steps, each of the variables is incremented individually to provide information 
of sensitivity of a parameter and direction of the gradient. Once a few initial objective 
functions are found via independent variable adjustment the optimization algorithm is 
applied. Calculation of a gradient at each step allows the optimization routine to seek 
out, in this case, the minimum. Typically large step  are taken when the gradient is 
steep, smaller steps in locations where the gradient is reduced. Variable step length 
improves the efficiency of the process, with little potential of stepping over the 
minimum.  
Optimization Function: fmincon 
In this optimization, the MatLab function ‘fmincon’ was used. Fmincon is a 
constrained, linear optimization code that searches for the minimum of a scalar 
function by adjusting several variables beginning with an initial guess. The objective 
of this study is to minimize the variability of deposition in the deep lung resulting 
from the variability in patient physiology. 
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The Objective Function  
Variance, standard deviation and the coefficient of variation (COV) all describe 
the dispersion of a data set, however, variance and standard deviation are both 
functions of the mean so their values are not easily compared across data sets. [17] 
For this reason, the dimensionless parameter COV was selected to be the minimizing 
function. The COV is a ratio of the standard deviation and the mean (see below) and 
as such is a normalized standard deviation. A smaller COV would indicate less 
variability in the data and vice versa.  
<%l  w? 
By minimizing COV ‘fmincon’ seeks small standard deviations and large mean 
depositions. In other words, the optimization is looking for a polydispersed spray that 
minimizes the variation across the deposition data but also maximizes the total 
volume deposited.  
Constraint Options 
Fmincon also offers a variety of constraint options i cluding, but not limited to 
setting bounds on the optimization variables. For this study, the optimization 
variables are the defining parameters of the distribution being studied. The 
distribution parameters and the bounds set on those parameters are summarized below 




Table 2.3: Distribution Parameter Bounds. This table summarizes the boundaries 
set on each distribution’s defining parameters. Thevariables x1, x2, etc. indicate that 
they are separate parameters optimized by fmincon. N te: The means and standard 
deviations are converted into microns within the code after the distribution has been 
established.  
  Variables Bounds 
Lognormal Mean (Normal) 1 ≤ x1 ≤ 7 
 
Standard Deviation (Normal) 0.6 ≤ x2 ≤ 3 
Normal Mean 1 ≤ x1 ≤ 7 
 
Standard Deviation 0.6 ≤ x2 ≤ 3 
Weibull Scale Factor 1≤ x1 ≤ 7 
 
Shape Factor 1 ≤ x2 ≤ 2.5 
Bimodal Mean (Normal) 1 ≤ x1 ≤ 7 
(Two Lognormal 
Distibutions) 
Standard Deviation (Normal) 0.6 ≤ x2 ≤ 3 
Mean (Normal) 1 ≤ x3 ≤ 7 
 
Standard Deviation (Normal) 0.6 ≤ x4 ≤ 3 
 
Weight 0 ≤ x5 ≤ 1 
 
It is also possible to control the optimization itself using the “optimset” option. 
The default options can sometimes cause an optimization to terminate prematurely or 
step over the minimum. For this reason, the options shown in Table 2.4 were utilized. 
Table 2.4: Fmincon Optimization Parameters. This table summarizes some of the 
key parameters set in fmincon for this optimization. 
Name Description Set Value 
TolFun 












Number of iterations for which the 
bound specified in 








CHAPTER THREE: RESULTS AND DISCUSSION 
 
 Before an “optimization” can be performed for the populations in question, 
certain investigations need to be accomplished.  First, relevant algorithms need to be 
validated. Next, evaluations of simpler problems can reveal the behavior of systems and 
aid in the setting of the optimization parameters as well as selection of deposition models.  
Finally, populations can be evaluated and optimal distributions found and compared. 
Validation of Optimization Code 
The results of this study are founded upon the successful execution of the 
optimization routine. To confirm that the optimization code works as it should, an 
optimization was set up modeling deposition in a horizontally oriented tube with a bend. 
The optimized parameter in this case was the angle, α, of the bend in the tube and the 
minimizing function was the negative coefficient of variation (“COV”).  Recall that the 
COV is σ/µ, so by minimizing -COV the optimization should seek to increase the COV to 
a point where the mean and standard deviation of deposition in the tube are equal, in 
other words COV=1. This should occur when zero particles deposit and therefore 
fmincon should optimize to a 0° bend angle which is a traight tube. The Cai and Yu 
equation discussed in chapter 2 was used with a diameter ratio of 1 to calculate 
deposition by impaction. The optimization was set up o vary the angle, α, from 0° to 90°. 
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The initial and optimized angle and corresponding values for COV are summarized 
below in table 3.1. 
Table 3.1: Optimization Validation Results. The value X is the optimized variable which 
is altered by fmincon to minimize the optimization fu ction, COV. 
 
The outcome of this effort demonstrates that the optimization utilized in this study 
performs as expected and can be used to minimize the COV of deposition in the lung for 
the remainder of this study.  
Variability with Flow Rate Study (21-Year-Old) 
       It is important to examine flow rate first to understand the behavior of the system 
under less complex conditions.  This will aid in the selection of the impaction model. 
Current Device Performance 
To understand current inhaler aerosol performance, the particle size distributions of a 
DPI and pMDI were recorded and the total volume of particles deposited in the last six 
generations of the lung was calculated over the range of flow rates from 10 to 30 L/min. 




Figure 3.1: Current pMDI and DPI Distributions. 
 
This deposited volume was then plotted against the corresponding flow rate to 
establish a baseline for the optimization, see Figure 3.2.  From this plot, the sensitivity of 
these aerosol delivery systems to flow rate was determined by fitting a linear trendline to 
the data where the sensitivity is represented by the slope of the trendline. This was 
performed for both CAI and Yu and Chan and Lippman equations so the differences 





Figure 3.2: Fraction of delivered dose deposited in the deep lung as a function of flow 
rate for current pMDI and DPI inhaler distributions. Top: Cai &Yu Correlation for 
deposition by impaction. Bottom: Chan & Lippmann correlation for deposition by 
impaction. 
 
It becomes evident when comparing the two graphs above that the deposition 
equations chosen have a significant impact on the deposition efficiency. The higher dose 
deposited when using the Cai and Yu correlation (Figure 3.2, top) indicates that these 
equations predict that fewer particles deposit in the upper generations and more reach the 
deep lung when compared to the Chan and Lippmann equations. This aligns with the 
validation performed in Chapter 2 where the Cai and Yu equation had much lower 
deposition than Chan and Lippmann for higher stokes numbers. Having established a 
y = -0.006x + 0.3475
R² = 0.934
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DPI - Chan & Lippmann
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baseline it is now productive to explore the effect of mean and span on the COV for a 
lognormal distribution. 
The Design Space 
Because particle diameter plays a major role in deposition it was hypothesized that 
altering the mean and standard deviation of a distribution would change the coefficient of 
variation (COV) and thus an optimization could be prformed which minimized 
variability with respect to flow rate and therefore improve deposition for a population. A 
parametric study was undertaken to reveal the objective function value over the design 
space using a lognormal distribution and to prove that he particle size distribution affects 
COV.  
The objective function of the lognormal spray distribution was evaluated using the 
Cai & Yu impaction equations over a range of mean 1 to 7 µm, span 0.6 to3 µm resulting 
in a COV value between 0.135 and 1.0. The figure below (Figure 3.3) exposes some of 
the data from that study and proves that the mean and standard deviation do affect the 
COV. It also indicates that a minimum, represented by the color purple, exists that can be 
sought by an optimization process. It is important to note that the entire design space 
evaluated is not presented in this figure so the exist nce of a plateau can be revealed more 
clearly. Plateaus occur when the steps taken by the optimization result in changes to the 
objective function within the function tolerance.  In other words the objective function 
(COV) does not change enough to justify continuing the optimization.  These plateaus 
can result in a premature termination of the optimization routine. Therefore, to ensure the 
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discovery of a global minimum, all optimizations were performed from various initial 
conditions.  
 




In addition to collecting more comprehensive data, it is important to explore the 
potential of different types of particle size distributions and to select an impaction 
correlation equation, therefore, an optimization was performed using the 21-year-old lung 
morphometry over a range of flow rates from 10 to 30 L/min in 1 L/min increments. This 
optimization of COV was run for four distributions of interest (normal, lognormal, 
bimodal, Weibull) and was compared to the baseline performance found previously in 




Table 3.2: Flow Rate Only Optimization Results. The m an and span of the lognormal 
distribution is the equivalent normal mean and span (see the methods chapter for the 
relationship). The weight associated with the first and second mean-span is the fraction of 
therapeutic designated to the corresponding peak.) 
Cai and Yu Impaction Correlation 
 












































Chan and Lippmann Impaction Correlation 
 













































Similar values for COV were obtained for all optimized distributions within the same 
impaction correlation data set. By performing an optimization, a significant improvement 
was made to COV with respect to the current PDI and MDI inhalers. This improvement 
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in COV was much less using the Cai and Yu equation tha  the Chan and Lippmann, 
however, the initial value of the COV was much lower for the Cai and Yu equation than 
it was for Chan and Lippmann. This discrepancy in COV can be explained by the 
predictive behaviors of the respective correlations. Recall that the Cai and Yu equation 
predicts much higher deposition efficiency in the lower airways (Figure 3.2) and in 
Chapter 2 the coefficient of variation was defined as the standard deviation divided by the 
mean. It can be seen in Table 3.2 that the standard eviations for both correlations are 
close, so the difference in COV must be driven by the denominator, the mean deposition. 
Because the mean deposition is considerably higher for the Cai and Yu case from the 
beginning, the resulting change in COV is much lessthan that for Chan and Lippmann.  
With this in mind, coefficients of variation from the four optimized distributions using 
the Chan and Lippmann impaction model were approximately half of the current 
distributions injected by commercial atomizer, where Cai and Yu COVs were only 
reduced by a couple percent. In both cases deposition efficiency improved by 20%, from 
~10% to ~30% for the Chan and Lippmann equation and from ~20% to ~40% for the Cai 




Figure 3.4: Optimized Distributions for Chan & Lippmann Impaction 
 
The Chan and Lippmann distributions for the lognormal, normal and the bimodal 
are nearly identical (Figure 3.4). In Table 3.2 it can be seen that the bimodal distribution 
optimized to one mode; the optimization put all of the therapeutic in one peak via the 
weighting. Only the Weibull distribution falls slightly away from the rest with a mode or 
peak particle diameter of closer to zero, and a span near 1 µm, which is difficult to 
physically generate.  Because of this similar shape in delivered particle size, the 
minimum COV value has a variation close to the convergence limit for the algorithm 
applied, thus all distributions should be considere identical in performance.  
These distributions have a mode very similar to that currently delivered by DPI and 
pMDI devices (Figure 3.1). The span, however, is dramatically smaller indicating a need 
for a more controlled spray.  
The polydispersity index is commonly used in industry to discern whether or not a 
distribution can be considered monodisperse. The polydispersity index specifies 
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distributions as monodisperse when the index is les than 1.2. This index is the mean by 
volume of the distribution divided by the mean by number.  The index for the optimized 
distributions close 1.04, which is well below the threshold, therefore the optimized 
distribution can be considered highly monodisperse. 
 
Figure 3.5: Optimized Distributions for Cai & Yu Impaction. 
 
Notice that the optimized distributions with Cai and Yu are also identical (Figure 
3.5), with the exception of the Weibull peak. The Wibull distribution had a mode below 
2 µm and a significantly larger span.  Although the minimum COV for Weibull is only 
0.21 compared to 0.22 for the others, it is outside the convergence tolerance limits of the 
optimization. Figure 3.5 also shows that although the weight is shared between the 
bimodal distribution peaks (Table 3.2), the bimodal peaks are on top of one another, so 
the distribution, like for Chan and Lippman, can be considered single valued. The Cai 
and Yu impaction correlation’s optimized distributions are different from those of Chan 
and Lippmann and current devices having a higher mean by nearly 1.5 µm. The 
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polydispersity index for the Cai and Yu distributions is approximately 1.04 as well and 
therefore the distributions optimized with the Cai and Yu deposition equation are also 
monodisperse.  
To quantify improvement over current devices, the optimized deposition data of the 
distributions were then compared to the MDI data as c n be seen below in Figure 3.6. 
Although the slopes of the lines in Figure 3.6 indicate a dependence on flow rate, the 
slopes are not what this study seeks to minimize. As discussed in Chapter 2, the 
coefficient of variation is the minimizing function and the slope represents the standard 
deviation which is the numerator of COV. The standard deviation is normalized by the 
mean in the denominator.  By optimizing in this way, the degree of dispersion from the 
mean is minimized rather than just the standard deviation itself. The standard deviation 
on its own speaks little of the actual variation because it is a function of the mean. For 
example, a population with a mean of 100 and a standard deviation of 25 actually has the 
same degree of dispersion as a population with a mean of 10 and a standard deviation of 
2.5, despite the drastically different standard deviations [Halder, 2000]. Neither the Chan 
and Lippmann nor the Cai and Yu optimizations reduc the slopes notably with respect to 
the baseline DPI slope (Figure 3.6), but they both improved the degree of dispersion from 





Figure 3.6: Fraction of delivered dose deposited in the deep lung as a function of flow 
rate for tested distributions. Top: Cai &Yu Correlation for deposition by impaction. 
 
The study conducted by Zanen et al., discussed in Chapter 1, found that particles with 
2.8 µm diameters deposited better to provide a higher therapeutic effect than both 1 and 5 
µm. For this reason, the Cai and Yi correlation was chosen to do the remainder of this 
study for deposition by impaction as it predicts an optimum closest to that found in 
clinical studies.  Furthermore, due to the fact thaall distributions behave similarly, the 
log normal and bimodal distributions were selected for the following optimizations. 
These distributions were selected because lognormal distributions are used in current 
commercial devices so incorporation of new distribution characteristics would be simple.  
In addition the second distribution could potentially improve deposition variation across 
populations.  
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Age/Weight and Flow Rate Variability Study  
Optimization for Adults Only 
With an impaction correlation and particle size distributions selected, an 
optimization seeking improved variability and depositi n across populations can be 
examined. In this section, variability in an adult cohort consisting of 21-, 18-, 14.08- and 
14 year-old lung cast data was analyzed over the same r nge of flow rates discussed in 
the previous section. When lung morphology as a result of an individual’s mass, was 
added into the optimization function, the COV increas d by 3 times what it was when 
only flow rate variability was considered. Under the conditions in this study, a variability 
of over 60% was observed in the pMDI /DPI performance. This is not surprising given 
the strong role lung morphometry plays in deposition; the introduction of variability to a 
critical parameter will increase the variability of the whole system. This increase in COV 
would explain the large variability observed in clinical settings. Although researchers 
have recognized physiology as a problem, most have downplayed its significance instead 
focusing only on variables that can be controlled like angle of injection etc.   
It was predicted that a significant improvement to deposition and variability could be 
achieved by employing an optimization strategy to the injected aerosol plume. In 
complex design spaces where both controllable and uncontrollable variables exist, a 
combination of design innovations can be used to manipulate the controllable variables to 
near optimal conditions and tune manufacturing tolerances to minimize the impact of 
uncontrollable variables.  However, it can be seen in Figure 3.7 that increasing the system 
complexity to include a range of adults did not shift the new optimized distribution far 
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from the flow-rate-only optimization above (only about 0.5 µm) and the optimized spray 
is still monodispersed.  
 
Figure 3.7: Optimized Bimodal and Lognormal Distributions. Top left: Bimodal 2. Top 
right: Bimodal 1. Bottom: Lognormal. 
 
The summary of the optimizations can be seen in Table 3.3. Only a small 
improvement in the COV is observed (<2%).  Although this satisfies the convergence 
criteria of the optimization, it does not appear to improve variable clinical outcomes at 
least in a measureable quantity. Moreover, there appe rs to be a slight tradeoff between 
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deposition efficiency and standard deviation. In all optimizations the mean volume of 
particles deposited across lung morphometry and flow rates is increased substantially, 
while the standard deviation is increased slightly. While this still greatly improves the 
deposition across a population, it was anticipated. The expected result was a wide 
distribution that would decrease standard deviation, perhaps to the detriment of volume 
deposited. Instead, like in the previous section, the optimization seeks to reduce the COV 
by increasing overall deposition (a 10% rise is observed which may be desirable) rather 
than reducing the standard deviation. This could be a r sult of a relatively small sample 
size that includes markedly different lung geometries which makes altering the standard 
deviation of deposition difficult because the mean deposition in each lung model is so 
different to begin with. The optimization searches for the best way to minimize the 
objective function, COV, and in this case, increasing the deposition efficiency across the 




Table 3.3: Flow Rate and Mass Optimization Results. The mean and span of the 
lognormal distribution is the equivalent normal mean and span (see methods chapter). 
Not all runs are represented in this table. The table summarizes the most interesting 
results from the optimization to demonstrate the potential of all distributions. 
Cai and Yu Impaction Correlation 
 




















































Another interesting outcome of this study pertains to the two different types of 
distributions evaluated. While the lognormal case optimized to the same distribution 
when initialized from different places, the bimodal distribution optimized to different 
locations maintaining the same coefficient of variation. This indicates that there is a 
plateau in which different combinations of lognormal distributions can yield the same 
COV.  In some cases the bimodal optimization the distribution did not remain bimodal; it 
converged to a single mode with the same optimized parameters as the lognormal 
distribution (Bimodal 2, Figure 3.7).  It did this by either putting all of the weight in a 
single peak or by shifting both peaks to be in the same location. The addition of the 
second peak (Bimodal 1, Figure 3.7) reduced the standard deviation with respect to the 
other optimizations while maintaining the same deposition efficiency. This is exactly 
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what was hypothesized for the second peak, however, as shown in Table 3.3 and Figure 
3.7, the second peak includes a large amount of particles less than one micron in 
diameter. Studies show that particles that small are often exhaled and do not actually 
deposit in the lung. A deeper exploration of this plateau region and the convergence 
criteria of the objective function could reveal a more realistic bimodal optimum.  
This optimization improved the mean deposition efficiency of an adult cohort 
from ~22% in current devices to ~32%. Consequently the coefficient of variation of 
deposition across morphometry and flow rate was also improved. The resulting 
distributions and population deposition information can now be compared, to those of 
outlier populations.  
Optimization for Adults with Lung Remodeling 
An optimization was performed on the adult cohort cnsisting of 21-, 18-, 14.08- and 14-
year-old lung models, like in the previous section, with an adjustment made to their 
airway diameters to simulate the remodeling which ocurs in the lung after many years of 
having severe asthma. These optimization results were then compared to those of the 




Table 3.4: Optimization Results for a Sample of Healthy and Remodeled lungs 
Healthy Adults 
Distribution Properties Optimization Results 
Distribution Type Mean 1 Span 1 Dep. Eff. St. Dev. COV 
pMDI 1.57 0.83 22.56% 1.72E-08 0.637 
DPI 1.36 0.73 21.68% 1.66E-08 0.639 
Optimized Lognormal 3.60 0.60 32.45% 2.42E-08 0.621 
Unhealthy Adults (Remodeling) 
Distribution Properties Optimization Results 
Distribution Type Mean 1 Span 1 Dep. Eff. St. Dev. COV 
pMDI 1.57 0.83 11.00% 9.15E-09 0.693 
DPI 1.36 0.73 10.05% 8.50E-09 0.705 
Optimized Lognormal 2.78 0.60 31.93% 2.40E-08 0.626 
 
The deposition efficiency for both the healthy and remodeled lung models were 
increased. The optimization of the injected spray for lungs with severe remodeling 
decreased the coefficient of variation from 0.7 to almost 0.6 despite the slight 
increase in standard deviation by tripling the depostion efficiency.  The healthy 
optimization only decreased the COV from 0.63 to 0.62, however the improvement in 
depsosition was significant, as discussed in the previous section. The deposition in the 
healthy and remodeled lungs were improved by approximately 15 and  35 percent 
respectively.  The resulting optimized distributions can be seen below in Figure 3.8 
where the means of optimal distributions for the healthy and remodeled lung differed 
by approximately one micrometer. It is important to n te that the airway diameters 
were adjusted in accordance with remodeling data therefore the changes to lung 
elasticity were not captured. A FSI (Fluid, Solid Interaction) computational model 
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would need to be developed to more accurately capture the deposition behavior in the 
lungs of severe asthmatics. 
 
 
Figure 3.8: Optimized Distribtions for Healthy and Remodeled Lung Morphometries. 
The optimized lognormal size distribution for an adult cohort of remodelled lungs can 
be seen on the left and the optimized lognormal size d stributionfor the same adult 
cohort without lung remodelling can be seen on the right.  
 
 
Figure 3.9: Deposition Efficiency as a Function of Flow Rate in Healthy and 





































 It can be seen above in the Figure 3.9, which represents the deposition in the 21-
year-old lung model,  that any increase in slope that resulted from the optimization is 
slight compared to the increase in deposition. In this adult population the sensitivity 
to velcocity is less critical than it would be in younger pateients due to the increased 
liklihood of overdose in children and infants. This most important thing to notice 
from this optimization which can be most easily seen in Figure 3.9 is that by 
optimizing the particle size distribution for the rmodeled lung morphometry, those 
adults who suffer from athsma induced remodeling are t ken from receiving almost 
no therapeutic at all to receiving the same amount of dose as the healthy adults. 
It is important to note here that an optimization encompassing both healthy and 
remodeled lungs was attempted but the optimized distribution didn’t change from that 
of the healthy adult. This is most likely due to the fact that the respective optimal 
distributions are so close to one another; differing by only one micrometer. However, 
as demonstrated above, a different injector for severe asthmatics would provide 
significant improvement from existing technologies. 
Optimization for Children 
  To explore optimization for yet another outlying population, the optimization 
performed for the adults was also compared to one of children younger than ten where 
lung cast data from a 1.75-, 1.92, 2.33 and a 3-year-old were used. Each age group, adults 
and children, was optimized twice; once with the COV as the objective function and 
again with standard deviation as the objective functio  to see how the optimization would 
behave. The results from the optimizations are summarized in Table 3.5.   
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Table 3.5: Summary of Adult and Children Cohorts Optimization 
Adult Lognormal Optimization 
Distribution Properties Optimization Results 
Optimized Function Mean 1 Span 1 COV Dep. Eff. St. Dev. 
pMDI 1.36 0.73 0.64 22.56% 1.72E-08 
DPI 1.57 0.83 0.63 21.98% 1.66E-08 
COV 3.63 0.60 0.63 33.24% 2.50E-08 
Standard Deviation 1.00 3.00 0.63 24.89% 1.90E-08 
Children Lognormal Optimization 
Distribution Properties Optimization Results 
Optimized Function Mean 1 Span 1 COV Dep. Eff. St. Dev. 
pMDI 1.36 0.73 1.09 2.00% 2.60E-09 
DPI 1.57 0.83 1.12 1.85% 2.49E-09 
COV 1.20 0.60 0.68 5.10% 4.19E-09 
Standard Deviation 7.00 0.60 1.95 0.54% 1.25E-09 
 
When the objective function was the standard deviation, the optimization ran to the 
boundaries where there is zero deposition. It can be seen in Figure 3.10 that a 3-year-old 
receives close to zero therapeutic with the distribu ion suggested by the optimization with 
the standard deviation as the objective function. This low deposition would be even 
worse in infants so there is even less room to sacrifice deposition for less variability. 
This, coupled with the optimization going to the boundary, concludes that optimizing the 
standard deviation in this way is not useful especially for children whose deposition 
efficiency is already extremely low. The adult stand rd deviation shows that there is 25% 
deposition efficiency for a mean of one micrometer but, as discussed earlier, particles 
with diameters less than one micrometer tend to be exhaled so the deposition efficiency is 




Figure 3.10: Deposition Efficiency as a Function of Flow Rate for a 21- and 3-year-
old. 
 
When the COV was used as the optimization function, significant improvement was 
made in the children cohort. The mean deposition effici ncy was increased from 2% to 
5% and the COV was reduced to 0.68 from over one. This is significant if you look at 
Figure 3.10 and consider the deposition for the 3-year-old. The pMDI distribution yields 
almost no deposition, and therefore a chance of no therapeutic effect at the higher flow 
rates. However, the optimized distributions yielded around 5 percent. This could mean 
the difference between life and death for a sick infant.  
y = -0.0077x + 0.5078
R² = 0.9703
y = -0.0064x + 0.3825
R² = 0.9651
y = -0.0083x + 0.1454
R² = 0.9733
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Figure 3.8: Optimized Lognormal Paticle Size Distribtions for Children and Adult 
lung Morphometries. Left: children cohort. Right: adult cohort  
 
With optimized distributions more than 2 microns apart (Figure 3.11), it was 
hypothesized that a dual-nozzle spray could be usedthat would satisfy both the adult and 
children cohorts. However, when the optimization was run with the adults and children 
together, the optimization algorithm went to the boundary. This is because the mean 
depositions of the two cohorts are so far apart (Figure 3.10). The optimization routine 
tries to bring the mean deposition closer together o reduce the COV but because of the 
vastly different geometries it cannot. So it optimizes to the boundaries where there is zero 
deposition just like it did for the optimizations using the standard deviation as the 




This optimization proves that one size distribution ca not work for all users and also 
suggests that an inhaler with two or more nozzles with different distributions can 
potentially be utilized to successfully dose the population. That being said, if one device 
with multiple nozzles is to be implemented, a study exploring the effects on deposition of 
each nozzle on all of the populations would need to be conducted to prevent overdosing, 
especially in children.   
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CHAPTER FOUR: CONCLUSION 
 
This analysis revealed that the Cai and Yu impaction model provided more 
clinically relevant deposition results in the deep lung for the techniques employed. It also 
exposed the criticality of choosing the correct empirically derived deposition model, to 
understanding the results of optimization.  Additionally, fluid-solid interaction (FSI) 
modeling is necessary to eradicate errors inherent in empirical models.  
In this instance, a lognormal distribution was used to optimize deposition 
coefficient of variation in the last six generations of the lung for a range of ages and flow 
rates which represent the variability in lung morphometry as a function of mass and 
health state. The normal, bimodal and Weibull distribu ions were also tested, but 
performance was the same across distributions. It should be noted, however, that there is 
potential for control of the standard deviation of deposition using a bimodal distribution. 
But further investigation of the objective function tolerance and the possible bimodal 
combinations is required.  
Minimizing the standard deviation did not result in a realistic optimization of the 
particle size distribution. The optimization seeks zero deposition to minimize the standard 
deviation and, as a result, the final distribution s at the bounds of the routine. This is 
undesirable because no therapeutic is actually deliver d and unrealistic because studies 
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show that particles larger than seven micron or smaller than one micron either do not 
make it into the lower regions of the lung or are exhaled. Consequently, not much can be 
done to improve the standard deviation of the population deposition efficiency using a 
single-peak distribution without drastically reducing the mean volume deposited. This is 
most likely a result of the study’s small sample size or  too great of a variation in 
deposition could be too great for the optimization t  work properly. A reduction in 
deposition could be acceptable in adult population where efficiency is greater, but in 
infants deposition efficiency is already extremely low, ~5%. Therefore,  a reduction could 
result in no therapeutic delivered at all. Unfortunately, low variability is also more critical 
in younger patients due to the stronger threat of overdose.  More research is needed to 
effectively and safely treat these patients using inhaled aerosols. 
In a population consisting of four healthy, adult lng models the mean deposition 
efficiency over the range of flow rates 10 to 30 L/min was improved from ~20% to ~30% 
when employing a monodisperse spray of 3.6 µm compared to current inhaler devices. 
An adult cohort population with severe lung remodeling over the same range of flow 
rates was also optimized. The resulting lognormal distribution improved deposition 
efficiency from ~10% to ~30% and the COV was reduced from ~0.7 to 0.62. It is 
important to emphasize that by optimizing the distribution the remodeled cohort took 
them from having little to no deposition from current devices to having the same 
deposition as the healthy cohort. This was achieved using a monodisperse spray of 
diameter 2.8 µm which suggests that having specialized particle distributions for this 
population might have measurable clinical impacts. Even when the changes in lung 
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elasticity are ignored, vast shifts in deposition and subsequently the optimal particle size 
distribution are evident. Lung remodeling, although not completely modeled in this study, 
should not be ignored in future work.  Here FSI (fluid-solid interaction) modeling would 
need to be employed to accurately characterize the be avior of the diseased lung. 
  In a children cohort consisting of a 1.75-, 1.92-, .33- and a 3-year-old, mean 
deposition efficiency was improved from ~2% to ~5% and the COV was reduced from 
~1 to ~0.68 when a monodisperse spray of 1.2 µm diameter particles was used. This 
improvement in mean deposition efficiency brings the deposition at higher flow rates 
from being at or near zero to somewhere between 5% and 10%. Current inhalers have 
little to no efficacy at higher flow rates, so for a crying infant or one suffering an asthma 
attack, both of which result in increased flow rates, this extra 5% deposition efficiency 
could mean life or death. 
The vast difference between adults and children in deposition suggests that a 
single device that outputs a single particle size for both populations is not advised. A 
multi-node distribution could, in fact, reduce the large variation in the mean deposition 
without sacrificing efficiency. Bimodal optimization were run for the adult cohort over a 
range flow rates from 10-30 L/min and the resulting distribution was dependent on the 
initial conditions and the convergence criteria of the optimization. Different combinations 
of two peaks resulted in the same COV with different mean deposition volumes and 
standard deviations. This is exactly what was hypothesized in the introduction; a 
combination of distributions can reduce the variation n deposition across a population. 
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Further investigation of this plateau could reveal that a combination of distributions 
emanating from two or more nozzles on a device can improve device reliability and 
efficacy over a larger population of patients.    
Important future work would be to further investigae the design space where 
there are plateaus in COV to see how much multi-node distributions can improve device 
reliability. This would benefit from an increase in the sample size so more lung cast data 
should be analyzed to properly represent the population. A multi-modal investigation of 
deposition overlap should also be considered so that overdosing, especially of children, 
can be avoided.  
Advances in computation could boost follow on studies. A pattern search 
algorithm could be used to seek out a global minimum as opposed to running the 
optimization from many different initial conditions. Also, more advanced computational 
methods could be employed, such as FSI modeling, to acc unt for inaccuracies in current 
statistical and empirical lung deposition models. It would even improve understanding in 
the areas of lung remodeling and lung elasticity. 
In sum, the complexities of the multiple variables that complicate optimal aerosol 
deposition in the lungs would greatly benefit from computational advances applied to 
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